Cannabis Compounds Offer New Hope for Fatty Liver Disease Treatment
Two non-psychoactive compounds found in the cannabis plant may hold the key to reversing metabolic dysfunction-associated steatotic liver disease (MASLD), a silent condition affecting approximately one quarter of the American population. Researchers from Israel have discovered that cannabidiol (CBD) and cannabigerol (CBG) can potentially reverse liver damage associated with this widespread chronic disorder.
The Global Burden of Fatty Liver Disease
MASLD represents the most common chronic liver condition worldwide, primarily driven by obesity, insulin resistance, hypertension, and elevated cholesterol levels. This metabolic disorder affects between 80 million and 100 million Americans, with many remaining unaware of their condition due to its typically asymptomatic nature in early stages.
For those who progress to more severe forms, MASLD can develop into metabolic dysfunction-associated steatohepatitis (MASH), characterized by inflammation and liver scarring. This progression can ultimately lead to cirrhosis, liver failure, and hepatocellular carcinoma, a particularly aggressive form of liver cancer.
Experimental Design and Methodology
Researchers at the Hebrew University of Jerusalem conducted experiments using male mice fed either standard diets or high-fat diets for fourteen weeks to induce obesity and metabolic dysfunction mirroring human MASLD conditions. Following this induction period, the mice were divided into three treatment groups receiving either CBD, CBG, or a placebo via injection for four weeks while maintaining their high-fat diets.
The dosing regimen involved gradual escalation, with CBD starting at five milligrams per kilogram of body weight and increasing to ten milligrams, while CBG began at 12.5 milligrams and escalated to 25 milligrams. Throughout the treatment period, researchers meticulously monitored body weight, body composition, and glucose tolerance before collecting liver tissue, blood samples, and other biological materials for comprehensive analysis.
Unexpected Metabolic Reprogramming
The compounds functioned differently than anticipated, bypassing classical cannabinoid receptors typically targeted by cannabis-related substances. Instead, CBD and CBG appeared to fundamentally reprogram liver metabolism, prompting the organ to utilize an alternative energy-buffering system not normally employed by hepatic tissue.
Treated mice demonstrated significant increases in phosphocreatine, a molecule serving as a rapid energy reserve for cells, alongside enhanced lysosomal activity. Lysosomes function as cellular cleanup and recycling centers, and their improved performance combined with increased phosphocreatine levels helped livers better manage toxic fat accumulation while reducing inflammation markers and insulin resistance.
Comprehensive Metabolic Improvements
The beneficial effects extended beyond hepatic tissue to produce whole-body metabolic enhancements. Mice receiving either CBD or CBG exhibited:
- Reduced cholesterol levels, particularly LDL ("bad") cholesterol
- Decreased overall fat mass
- Increased lean muscle mass
- Improved glucose tolerance and normalized fasting glucose levels
- Lowered triglyceride concentrations
- Enhanced insulin sensitivity as measured by HOMA-IR scores
Remarkably, these improvements occurred despite the mice continuing their high-fat Western-style diets, suggesting the compounds enhanced liver resilience against excess fat and energy dysregulation.
Molecular Mechanisms and Lipid Alterations
Comprehensive lipid analysis revealed that CBD and CBG didn't merely reduce liver fat content but fundamentally altered hepatic lipid composition. Triglycerides—the primary component of fatty liver—accounted for nearly half of all decreased lipids following treatment. Ceramides, fats associated with insulin resistance and metabolic inflammation, were also significantly reduced.
Simultaneously, the compounds elevated levels of several phospholipids, including specialized lysobisphosphatidic acids (LBPAs) concentrated within lysosomes. This increase corresponded with improved lysosomal function, suggesting enhanced clearance of harmful fats through cellular recycling mechanisms.
The Creatine Energy Buffer System
Researchers discovered that treated mice developed elevated levels of creatine and phosphocreatine within their livers, creating an energy-buffering system more commonly associated with muscular tissue than hepatic cells. This adaptation essentially provided livers with a novel mechanism to manage energy stress induced by obesity and high-fat diets, restoring and even increasing the organ's energy reserves.
Clinical Implications and Cautions
The study authors emphasize that "despite the increasing clinical burden of MASLD, no pharmacological treatments have been approved to date," highlighting the urgent need for novel therapeutic agents targeting underlying disease mechanisms. While these findings are promising, researchers caution that the precisely calibrated compounds used in their experiments differ significantly from commercially available products.
Commercial CBD and CBG formulations vary widely in concentration, purity, and bioavailability, with none having undergone human clinical trials specifically for fatty liver disease treatment. Both compounds remain federally legal in the United States, with CBD commonly marketed for stress relief, anxiety management, pain reduction, and sleep support, while CBG is often promoted for inflammation reduction, mental clarity enhancement, and digestive issue alleviation.
As obesity and diabetes rates continue climbing globally, increasing the population affected by MASLD, these findings offer potential pathways for future therapeutic development while underscoring the necessity for rigorous human clinical trials to validate these promising preclinical results.
